In fact, a study by Kozloski et al. reported that miR-181a is a negative regulator of the NF-kB signaling pathway in DLBCL cells, inhibiting tumor cell proliferation and viability [62]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.